子宫颈神经内分泌肿瘤:妇科肿瘤学家的治疗挑战
子宫颈神经内分泌肿瘤占宫颈肿瘤的0.9%至1.5%,较常见宫颈鳞癌或腺癌更易发生淋巴血管间隙浸润和淋巴结转移,并出现局部和远处复发。世界卫生组织分类将宫颈类癌和非典型类癌归为低级别NET,将小细胞和大细胞神经内分泌癌归为高级别NET。由于肿瘤罕见,目前尚无基于前瞻性、设计良好的临床试验的治疗指南,本文系统综述其组织学分类、发病机制、预后及文献报道的不同治疗方式,以提供可能的诊疗算法。
要点
- 宫颈NET占宫颈肿瘤的0.9%至1.5%,较鳞癌或腺癌更易发生淋巴血管间隙浸润和淋巴结转移。
- 几乎全部宫颈高级别NET中可检测到高危型HPV DNA。
- 因肿瘤罕见,目前尚无基于前瞻性、设计良好的临床试验的治疗指南。
核心结论
- 本文系统综述宫颈NET的组织学分类、发病机制、总体预后及文献报道的不同治疗方式,旨在提供可能帮助临床医生诊断和治疗这类罕见且侵袭性恶性肿瘤的算法。
研究设计与样本
- 系统综述,分析文献中描述的宫颈NET的不同治疗方式。
主要发现
- 宫颈NET占宫颈肿瘤的0.9%至1.5%,较常见宫颈鳞癌或腺癌更易发生淋巴血管间隙浸润和淋巴结转移,并出现局部和远处复发。
- 宫颈NET中常检测到突触素、嗜铬粒蛋白、CD56和神经元特异性烯醇化酶的阳性免疫染色。
- 世界卫生组织妇科肿瘤分类最新版将宫颈类癌和非典型类癌归为低级别NET,将宫颈小细胞神经内分泌癌和大细胞神经内分泌癌归为高级别NET。
- 几乎全部宫颈高级别NET中可检测到高危型HPV DNA。
关键数值与推荐
- 宫颈NET占宫颈肿瘤的0.9%至1.5%。
- 世界卫生组织分类将宫颈类癌和非典型类癌归为低级别NET,将宫颈小细胞神经内分泌癌和大细胞神经内分泌癌归为高级别NET。
- 几乎全部宫颈高级别NET中可检测到高危型HPV DNA。
临床怎么用
- 许多作者报道了不同的多模式方法,主要源自肺NET,通常包括早期疾病行根治性子宫切除术后辅助化疗或同步放化疗;局部晚期疾病行 definitive 同步放化疗,有时前有新辅助化疗、后有辅助化疗;转移性疾病行姑息性化疗。
- 原文未据此给出推荐。
局限性
- 由于这些肿瘤罕见,目前尚无基于前瞻性、设计良好的临床试验的治疗指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Neuroendocrine tumors (NETs) are aggressive diseases developing from neuroendocrine cells that most frequently involve the gastro-entero-pancreatic tract and the lung, but more rarely are found in almost all body tissues. Limited biological and clinical data are currently available for NETs in uncommon sites, such as female genital tract. NETs represent 0.9% to 1.5% of the tumors of the uterine cervix. They are more likely to have lymph-vascular space invasion and lymph node involvement, and to develop local and distant relapses when compared with the mostly common cervical squamous cell carcinomas or adenocarcinomas. Positive immunostaining for synaptophysin, chromogranin, CD56, and neuron-specific enolase is often detected in cervical NETs . The most recent editions of the World Health Organization Classification of Gynecologic Tract tumors grouped cervical carcinoid tumor and atypical carcinoid tumor into low-grade NETs and cervical small cell neuroendocrine carcinoma and large cell neuroendocrine carcinoma into high-grade NETs. High-risk HPV DNA is detected in almost all cervical high-grade NETs. No treatment guidelines, based on prospective, well-designed clinical trials, are currently available due to the rarity of these tumors. Many authors have reported different multimodality approaches, mainly derived from NETs of the lung. These usually consist in radical hysterectomy followed by adjuvant chemotherapy or concurrent chemoradiation for early stage disease, definitive concurrent chemoradiation sometimes preceded by neoadjuvant chemotherapy and followed by adjuvant chemotherapy for locally advanced disease, and palliative chemotherapy for metastatic disease. In this systematic review, we address the histologic classification of cervical NETs, analyze their pathogenesis and overall prognosis, and evaluate the different treatment modalities described in the literature, in order to offer a possible algorithm that may help the clinicians in diagnosing and treating patients with these uncommon and aggressive malignancies.
引用
- Gadducci A, Carinelli S, Aletti G, et al. Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists. Gynecol Oncol. 2017. PMID: 28057354. doi:10.1016/j.ygyno.2016.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。